Photo for representation
Bhubaneswar: National Technical Advisory Group on Immunization (NTAGI) has approved Serum Institute of India’s COVID-19 vaccine Covovax for the 12-17 age group, sources told news agency ANI on Friday.
Notably, an expert panel of the country’s central drug authority recommended granting emergency use authorisation (EUA) to Covovax for this age group subject to certain conditions, on March 9. Subsequently, the Pune-based firm started to pursue regulatory permissions and its protocol.
Covovax has been developed through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation.
India began inoculating children aged 12-14 on March 16 with Biological E’s Corbevax.
Cuttack: A promising youthful life ended in Cuttack on Sunday as a sophomore was electrocuted…
Mumbai: Ever since ‘Kantara’ became a phenomenal hit in 2022, movie lovers have been yearning…
Bhubaneswar: The husband of a sarpanch and a panchayat samiti member were critically injured as…
New Delhi: Pollution in the national Capital is going from bad to worse. As Delhi’s air…
Bhubaneswar: In order to streamline the road construction works, the Odisha government is planning to…
Patna: The trailer of ‘Pushpa 2: The Rule’, one of the year’s most anticipated films, is…
Patna: It was one of the most anticipated events in the Indian film industry -- the…
Bhubaneswar: With Odisha government taking a serious note of unnatural death of elephants, the Forest…